Kura Oncology’s darlifarnib combination shows encouraging early activity, but its development in an unselected population is severely undermined by a history of farnesyltransferase inhibitor (FTI) class failures. The Phase 1a FIT-001 trial data, with an objective response rate of 33-50% and a median progression-free survival of 13 months, appears promising on the surface. However, this strategy directly contradicts the clear lesson from FTI precedents: combinations in unselected solid tumor populations consistently fail, as seen with tipifarnib plus gemcitabine in a large Phase 3 pancreatic cancer trial (P=0.75) and tipifarnib plus letrozole in breast cancer. Conversely, the only FTI successes, such as tipifarnib in HRAS-mutant HNSCC (55% ORR) and specific lymphoma subtypes, have been achieved in biomarker-selected populations. Without a defined biomarker, darlifarnib will struggle to gain regulatory approval or secure favorable market access, as payers will be skeptical of covering a costly combination over cabozantinib monotherapy. Further, a critical safety precedent of tipifarnib combined with sorafenib in RCC causing invasive cutaneous cancers raises specific concerns for this FTI and multikinase inhibitor pairing. The program's greatest risk is not the drug's activity, but a strategy that ignores the class's well-documented development history.
Data is from a small, uncontrolled Phase 1a study. The development strategy in an unselected population contradicts the FTI class history, where all successful programs required biomarker selection.
| Indication | Clear Cell Renal Cell Carcinoma |
| Drug | Darlifarnib and Cabozantinib |
| Mechanism of Action | Farnesyl transferase inhibitor, Tyrosine kinase inhibitor |
| Company | Kura Oncology, Inc. |
| Trial Phase | Phase 1a, Phase 1b |
| Trial Acronym | FIT-001 |
| NCT ID | NCT06026410 |
| Category | Clinical Trial Event |
| Sub Category | Topline Results Positive |
| Therapeutic Area | Oncology |
| Objective Response Rate | 33% to 50% |
| Median Progression-Free Survival | 13 months |
| Patient Population Size (Efficacy) | 34 |
| Patient Population (Description) | cabozantinib-naïve, pre-treated, locally advanced or metastatic ccRCC patients |
| Conference Name | 2026 Kidney Cancer Research Summit (KCRS) |
| Comparator Arm (Phase 1b) | Cabozantinib alone |
| Planned Registrational Study Year | 2028 |
| Enrollment Geographies | U.S., E.U. |
| Line of Therapy | second- and third-line RCC settings |
Kura Oncology Reports Durable Darlifarnib/Cabozantinib Activity in ccRCC
Kura Oncology announced updated Phase 1a results from the FIT-001 clinical trial, demonstrating encouraging and durable clinical activity of darlifarnib plus cabozantinib in cabozantinib-naïve patients with advanced clear cell renal cell carcinoma (ccRCC). The combination achieved objective response rates of 33% to 50% across evaluated dose levels and a median progression-free survival of 13 months. The safety profile was manageable and consistent with individual agents. These findings, presented at the 2026 Kidney Cancer Research Summit (KCRS), support continued development, including dose selection for the randomized Phase 1b portion of the study, which will compare the combination against cabozantinib alone.
- The combination of darlifarnib and cabozantinib demonstrated significant antitumor activity in pre-treated, cabozantinib-naïve, locally advanced or metastatic ccRCC patients. Objective response rates ranged from 33% to 50% across evaluated dose levels, with a median progression-free survival of 13 months, comparing favorably with historical outcomes for monotherapies.
- The darlifarnib plus cabozantinib combination was well tolerated across all dose levels, including when administered with full-dose cabozantinib. The safety and tolerability profile was generally consistent with the reported profiles of the individual agents, with neutropenia successfully managed through dose interruption/reduction and supportive care.
- These updated Phase 1a data are informing the dose combinations for the ongoing randomized Phase 1b portion of the FIT-001 study, which is enrolling patients in the U.S. and E.U. This Phase 1b study will evaluate darlifarnib plus cabozantinib versus cabozantinib alone to establish a recommended Phase 3 dose for a planned registrational study in 2028, targeting an important cabozantinib-naïve patient population.
Addressing Unmet Needs in Pretreated Cabozantinib-Naïve ccRCC
Despite significant advances in first-line combination therapies for clear cell renal cell carcinoma (ccRCC), major unmet needs persist for pretreated patients. Acquired resistance to immune checkpoint inhibitors (ICIs) and tyrosine kinase inhibitors (TKIs) severely limits long-term survival, creating a critical need for effective and durable later-line treatment strategies for patients who are naïve to subsequent therapies like cabozantinib.
Acquired Drug Resistance: A primary challenge is the development of resistance to targeted therapies and immunotherapies. Tumor heterogeneity contributes significantly to this issue, leading to variable patient responses and a frequent loss of treatment efficacy over time, particularly for those who progress after first-line ICI-TKI combinations.
Absence of Later-Line Standards: There is no established standard of care for patients whose disease progresses after first-line therapy. Recent clinical findings suggest ICI rechallenge should be discouraged, and combination strategies in the second-line setting have not yet demonstrated a significant advantage, highlighting a major gap in the treatment sequence.
Lack of Predictive Biomarkers: A critical need exists for reliable biomarkers to guide patient selection and personalize treatment. The absence of dependable markers to predict response or resistance restricts the clinical application of targeted agents and immunotherapies, making it difficult to optimize later-line therapeutic choices.
Emerging Therapeutic Targets: Research is focused on novel mechanisms for patients who have progressed on ICIs and VEGFR-TKIs. Key areas of investigation include targeting HIF-2α with inhibitors like belzutifan, exploring alternative cell death pathways such as cuprotosis and ferroptosis, and developing PSMA-targeted radiopharmaceutical therapies for advanced, PSMA-positive ccRCC.
Frequently Asked Questions
References
- [1] Cui Z, Wang N et al.. Asparagine-linked glycosyltransferase 6 deficiency suppresses tumorigenesis in clear cell renal cell carcinoma by regulating apoptosis and immunotherapy sensitivity. Chinese medical journal. 2026 Jun 29. 42374693
- [2] Huang R, Kee L et al.. Comparative single-cell transcriptomic profiling of patient-derived renal carcinoma cells in cellular and animal models of kidney cancer. FEBS open bio. 2025 Jul. 40241258
- [3] Waddell T, Pillai M et al.. Real-world effectiveness of first- and second-line anti-angiogenesis therapy in RCC: analysis of a UK-based population. Future oncology (London, England). 2024. 39382446
- [4] Lin YC, Sun DP et al.. Targeting CK1δ and CK1ε as a New Therapeutic Approach for Clear Cell Renal Cell Carcinoma. Pharmacology. 2024. 38955142
- [5] Zhu Y, Li Y et al.. Targeting Hypoxia and Autophagy Inhibition via Delivering Sonodynamic Nanoparticles With HIF-2α Inhibitor for Enhancing Immunotherapy in Renal Cell Carcinoma. Advanced healthcare materials. 2024 Dec. 39396375
- [6] Hu P, Chen D et al.. Comprehensive Whole-Course Management Strategy for Recurrent Renal Cell Carcinoma: Case Report and Literature Review. Clinical case reports. 2025 May. 40321230
- [7] Abdullah H, Zickuhr GM et al.. Kidney tumoroid characterisation by spatial mass spectrometry with same-section multiplex immunofluorescence uncovers tumour microenvironment lipid signatures associated with aggressive tumour phenotypes. Npj imaging. 2025 Sep 16. 40957946
- [8] Tang Y, Zhang C et al.. Construction and validation of programmed cell death-based molecular clusters for prognostic and therapeutic significance of clear cell renal cell carcinoma. Heliyon. 2023 May. 37305457
- [9] Wang K, Kong F et al.. Integrative multi-omics reveal NSUN2 facilitates glycolysis and histone lactylation-driven immune evasion in renal carcinoma. Genes and immunity. 2025 Aug. 40413354
- [10] Wang H, Chen Y et al.. MAGI3 enhances sensitivity to sunitinib in renal cell carcinoma by suppressing the MAS/ERK axis and serves as a prognostic marker. Cell death & disease. 2025 Feb 16. 39956807
- [11] Küronya Z, Lénárt E et al.. Sustained complete remission with third-line nivolumab in advanced renal cell carcinoma: a case report. Journal of medical case reports. 2026 Feb 25. 41742276
- [12] Zhang C, Song Y et al.. Regulatory T cells and matrix-producing cancer associated fibroblasts contribute on the immune resistance and progression of prognosis related tumor subtypes in ccRCC. Scientific reports. 2025 Jul 1. 40596367
- [13] Qi X, Wang J et al.. The potential value of cuprotosis (copper-induced cell death) in the therapy of clear cell renal cell carcinoma. American journal of cancer research. 2022. 36119838
- [14] Chen YW, Panian J et al.. Recent Developments in the Management of Renal Cell Cancer. JCO oncology practice. 2025 Oct. 40048685
- [15] Doyya M, Alloush G et al.. Renal cell carcinoma accompanied by aldosterone-secreting contralateral adrenal metastasis: a case report. Journal of medical case reports. 2025 Jul 9. 40635059
- [16] Liao Z, Yao H et al.. Development and validation of the prognostic value of the immune-related genes in clear cell renal cell carcinoma. Translational andrology and urology. 2021 Apr. 33968649
- [17] Tian X, Liu J et al.. Hsa_circ_0072732 enhances sunitinib resistance of renal cell carcinoma by inhibiting ferroptosis. Discover oncology. 2024 Nov 23. 39580569
- [18] Hilser T, Darr C et al.. [Contemporary treatment of metastatic clear cell renal cell carcinoma]. Urologie (Heidelberg, Germany). 2024 Dec. 39545945
- [19] Zheng B, Liu K et al.. GAMT facilitates tumor progression via inhibiting p53 in clear cell renal cell carcinoma. Biology direct. 2025 Apr 2. 40176130
- [20] Zhang YS, Pei XQ et al.. PRDM1 Knockdown Promotes Ferroptosis and Sunitinib Sensitivity by Modulating the PI3K/Akt Signaling Through Inhibition of ESM1 Transcription in Renal Cell Carcinoma. The Kaohsiung journal of medical sciences. 2026 Feb 16. 41693648
Contact Us
Address
One Research Ct, Suite 450
Rockville, MD 20850
For General Inquiry
info@pienomial.com
